Quick Answer
Krystal Biotech, Inc. reported Total Revenue of $389.13 million for fiscal year 2025.
Krystal Biotech, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $389.13M +33.9% |
$290.51M +473.0% |
$50.70M | $0.00 | $0.00 | — |
| Revenue (ASC 606) | $389.13M +33.9% |
$290.51M +473.0% |
$50.70M | $0.00 | $0.00 | — |
| Net Income | $204.83M +129.7% |
$89.16M +715.6% |
$10.93M +107.8% |
-$139.97M -101.2% |
-$69.57M -116.3% |
-$32.17M -68.5% |
| Diluted EPS | $6.84 +128.0% |
$3.00 +669.2% |
$0.39 +107.1% |
-$5.49 -75.4% |
-$3.13 -83.0% |
-$1.71 |
| Total Assets | $1.33B +26.3% |
$1.06B +29.0% |
$818.36M +46.5% |
$558.45M -10.8% |
$626.29M +101.5% |
$310.84M +48.7% |
| Cash and Equivalents | $496.30M +43.9% |
$344.87M -3.8% |
$358.33M +121.3% |
$161.90M -52.6% |
$341.25M +27.2% |
$268.27M +43.1% |
| Stockholders Equity | $1.22B +28.9% |
$946.38M +21.5% |
$778.64M +49.1% |
$522.23M -12.0% |
$593.58M +103.2% |
$292.08M +43.9% |
| R&D Expense | $58.05M +8.3% |
$53.58M +15.4% |
$46.43M +9.4% |
$42.46M +52.3% |
$27.88M +55.5% |
$17.94M +14.9% |
| Operating Income | $161.29M +145.3% |
$65.75M +160.0% |
-$109.62M +24.5% |
-$145.20M -112.7% |
-$68.28M -106.9% |
-$33.00M -49.4% |
| Shares Outstanding | 29.19M +1.4% |
28.79M +2.0% |
28.24M +9.6% |
25.76M +2.2% |
25.21M +27.9% |
19.71M +13.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $97.80M | +16.6% | +1.8% |
| Revenue (ASC 606) | September 30, 2025 | $97.80M | +16.6% | +1.8% |
| Net Income | September 30, 2025 | $79.36M | +192.0% | +107.0% |
| Diluted EPS | September 30, 2025 | $2.66 | +192.3% | +106.2% |
| Total Assets | September 30, 2025 | $1.24B | +26.2% | +8.9% |
| Cash and Equivalents | September 30, 2025 | $392.60M | +5.0% | +11.0% |
| Stockholders Equity | September 30, 2025 | $1.14B | +28.5% | +9.3% |
| R&D Expense | September 30, 2025 | $14.59M | +7.9% | +1.2% |
| Operating Income | September 30, 2025 | $41.37M | +84.1% | +5.3% |
| Shares Outstanding | September 30, 2025 | 28.98M | +0.8% | +0.2% |
- Krystal Biotech, Inc. reported Total Revenue of $389.13 million for fiscal year 2025.
- Krystal Biotech, Inc. showed an increase of +33.9% in Total Revenue compared to the prior fiscal year.
- Krystal Biotech, Inc. reported Revenue (ASC 606) of $389.13 million for fiscal year 2025.
- Krystal Biotech, Inc. showed an increase of +33.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Krystal Biotech, Inc. reported Net Income of $204.83 million for fiscal year 2025.
- Krystal Biotech, Inc. showed an increase of +129.7% in Net Income compared to the prior fiscal year.
- Krystal Biotech, Inc. reported Diluted EPS of $6.84 per share for fiscal year 2025.
- Krystal Biotech, Inc. showed an increase of +128.0% in Diluted EPS compared to the prior fiscal year.
- Krystal Biotech, Inc. reported Total Assets of $1.33 billion for fiscal year 2025.
- Krystal Biotech, Inc. showed an increase of +26.3% in Total Assets compared to the prior fiscal year.
- Krystal Biotech, Inc. reported Cash and Equivalents of $496.30 million for fiscal year 2025.
- Krystal Biotech, Inc. showed an increase of +43.9% in Cash and Equivalents compared to the prior fiscal year.
- Krystal Biotech, Inc. reported Stockholders Equity of $1.22 billion for fiscal year 2025.
- Krystal Biotech, Inc. showed an increase of +28.9% in Stockholders Equity compared to the prior fiscal year.
- Krystal Biotech, Inc. reported R&D Expense of $58.05 million for fiscal year 2025.
- Krystal Biotech, Inc. showed an increase of +8.3% in R&D Expense compared to the prior fiscal year.
- Krystal Biotech, Inc. reported Operating Income of $161.29 million for fiscal year 2025.
- Krystal Biotech, Inc. showed an increase of +145.3% in Operating Income compared to the prior fiscal year.
- Krystal Biotech, Inc. reported Shares Outstanding of 29.19 million shares for fiscal year 2025.
- Krystal Biotech, Inc. showed an increase of +1.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: